Premium
Solitary Mastocytoma Treated with Tranilast
Author(s) -
Katoh Norito,
Hirano Shinya,
Yasuno Hirokazu
Publication year - 1996
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1996.tb04026.x
Subject(s) - tranilast , mastocytoma , discontinuation , medicine , degranulation , pharmacology , histamine , azelastine , mast cell , chemotherapy , gastroenterology , dermatology , immunology , receptor , cancer research , tumor cells
Two infants with solitary mastocytoma were treated with 5 mg/kg/day of tranilast [N‐(3‘,4‘‐dimethoxycinnamoyl)anthranilic acid], a mast cell stabilizing compound extracted from Nandina domestica . Tranilast was administered orally in three divided doses. In one infant, a topical corticosteroid was also applied in combination with the oral tranilast. Patients experienced symptomatic relief, and nodules resolved almost completely after eight weeks of treatment Tranilast therapy was continued for six months. No relapses were observed after discontinuation of therapy. We speculated that tranilast not only inhibited mast cell degranulation but also reduced the number of mast cells.